Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...